« Return to News | Clinical Intelligence

Alize licenses Asparec therapy for treatment of leukemia

Monday, February 6, 2012 02:08 PM

Alize Pharma II, a drug development company focused on oncology and metabolism and part of the Alize Pharma group, has signed a license agreement with EUSA Pharma for Asparec, a new L-asparaginase product currently in phase I clinical development for the treatment of acute lymphoblastic leukemia.

Pursuant to the agreement, EUSA will be responsible for the development and worldwide commercialization of Asparec, targeted at patients with Acute Lymphoblastic Leukemia who are hypersensitive to E. coli-derived L-asparaginase. In return, Alize has received an upfront payment and will be entitled to additional regulatory milestone payments and royalties on sales. The companies have not disclosed further financial information.

This agreement between Alize Pharma and EUSA Pharma,” said Alize Pharma’s president and founder, Thierry Abribat, “validates our medical approach, emphasizes our drug development capabilities and fits well with our business strategy, which is to establish partnerships with the pharmaceutical industry early in the development of our programs in order to secure both near-term and long-term revenue streams.

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

December 17

Medici Global says its Alzheimer's Facebook page demonstrates the need for more early detection trials

Analysts: Expect more equity purchases of CROs in 2013

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

January 2013

Parexel celebrates 30 years of change, growth
CRO's founder and chairman reflects on challenges of the past, present and future

Strategies for increasing patient diversity in trials
Sponsors look to improve racial, ethnic recruitment without going overseas

Already a subscriber?
Log in to your digital subscription.

Purchase the January issue.

Subscribe to The CenterWatch Monthly.

December 2012

Publicity, regulation tightening reins on use of KOLs
Debate rages over need to revamp how sponsors use, pay medical experts

Time may be right to makeover the investigator brochure
Size, complexity prevent critical document from being thoroughly read

Already a subscriber?
Log in to your digital subscription.

Purchase the December issue.

Subscribe to The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.